LC
YMAB

Lindbrook Capital’s Y-mAbs Therapeutics YMAB Stock Holding History

Lindbrook Capital’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32
Closed -$421 – 2923
2024
Q3 		$421 Buy
+32
New +$406 ﹤0.01% 2710
2022
Q4 		– Sell
-606
Closed -$9K – 3032
2022
Q3 		$9K Buy
606
+6
+1% +$99 ﹤0.01% 1392
2022
Q2 		$9K Sell
600
-74
-11% -$863 ﹤0.01% 1321
2022
Q1 		$8K Buy
674
+623
+1,222% +$6.4K ﹤0.01% 1410
2021
Q4 		$1K Buy
+51
New +$1.09K ﹤0.01% 2021

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's YMAB Position: Q4 2024 in Review

Lindbrook Capital sold out of Y-mAbs Therapeutics (YMAB) in Q4 2024, closing a stake of 32 shares — an estimated $421 sold.

Lindbrook Capital first reported a position in YMAB in Q4 2021 and held it in 5 quarters. The position peaked at $9K in Q3 2022. 112 funds tracked by Wall St. Rank hold YMAB as of Q4 2024.

  • Lindbrook Capital reported no remaining Y-mAbs Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lindbrook Capital sold 32 Y-mAbs Therapeutics shares in Q4 2024, an estimated $421.
  • Lindbrook Capital first reported a position in Y-mAbs Therapeutics in Q4 2021 and held it in 5 quarters.
  • Lindbrook Capital's Y-mAbs Therapeutics position peaked at $9K in Q3 2022.
  • 112 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2024.

Based on Lindbrook Capital's 13F filing for Q4 2024, filed 6 Feb 2025.